146650-65-9

Basic information

• Product Name: (5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL
• Synonyms: (5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL
• CAS NO: 146650-65-9
• Molecular Formula: C₆H₉ClN₂O
• Molecular Weight: 160.6
• Mol File: 146650-65-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL(146650-65-9)
• EPA Substance Registry System: (5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL(146650-65-9)

Safety Data

• Hazardous Substances Data: 146650-65-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, potentially offering novel therapeutic options for a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, (5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL is utilized as a precursor in the synthesis of agrochemicals. Its imidazole-based structure may contribute to the creation of new pesticides or other agricultural chemicals that can enhance crop protection and yield.
Used in Medicinal Chemistry Research:
(5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL is employed as a research compound in medicinal chemistry. Its potential pharmacological properties make it a valuable tool for scientists to study and understand the mechanisms of action of imidazole-based drugs, leading to the discovery of new therapeutic agents.
Used in Drug Development:
As a compound with potential pharmacological properties, (5-CHLORO-2-ETHYL-1H-IMIDAZOL-4-YL)-METHANOL is used in drug development to explore its therapeutic potential. Further research and testing are required to determine its specific properties, efficacy, and safety, which could eventually lead to its incorporation into new drug formulations.

Upstream product

• 72993-43-2 2-ethyl-5-hydroxymethyl-1H-imidazole 
• 123-91-1 1,4-dioxane 
• 94388-89-3 2-ethyl-4,5-bis(hydroxymethyl)-imidazole 
• 87-90-1 trichloroisocyanuric acid 
• 124-38-9 carbon dioxide 
• 1093261-74-5 N-{1-cyano-2-[(phenylmethyl)oxy]ethyl}propanamide 
• 1093261-76-7 4-chloro-2-ethyl-5-{[(phenylmethyl)oxy]methyl}-1H-imidazole 
• 33457-50-0 (1-ethyl-1H-imidazole-4,5-diyl)-bis-methanol 

Downstream Products

• 146650-73-9 ethyl 1-[[3-bromo-2-(2-aminophenyl)-5-benzofuranyl]methyl]-4-chloro-2-ethyl-1H-imidazole-5-carboxylate 
• 145824-16-4 1-[[3-Bromo-2-[2-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-chloro-2-ethyl-1H-imidazole-5-carboxaldehyde 
• 145824-18-6 3-[3-Bromo-2-(2-tert-butoxycarbonylamino-phenyl)-benzofuran-5-ylmethyl]-5-chloro-2-ethyl-3H-imidazole-4-carboxylic acid 
• 146650-79-5 1-[[3-Bromo-2-[2-[[(trifluoromethyl)sulphonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-chloro-2-ethyl-1H-imidazole-5-carboxylic acid 
• 146650-71-7 ethyl 1-[[3-bromo-2-[2-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-chloro-2-ethyl-1H-imidazole-5-carboxylate 
• 146650-76-2 Ethyl 1-[[3-bromo-2-[2-[[(trifluoromethyl)sulphonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-chloro-2-ethyl-1H-imidazole-5-carboxylate 
• 1093255-18-5 4-chloro-N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-2-ethyl-1H-imidazole-5-carboxamide 
• 1093256-30-4 4-chloro-N-({4-chloro-3-[(3-chloro-5-cyclopropylphenyl)oxy]-2-fluorophenyl}methyl)-2-ethyl-1H-imidazole-5-carboxamide trifluoroacetate 
• 1093256-28-0 4-chloro-N-{[4-chloro-3-({3-chloro-5-[(E)-2-cyanoethenyl]phenyl}oxy)-2-fluorophenyl]methyl}-2-ethyl-1H-imidazole-5-carboxamide 
• 1093262-89-5 4-chloro-N-({4-chloro-3-[(3-chloro-5-formylphenyl)oxy]-2-fluorophenyl}methyl)-2-ethyl-1H-imidazole-5-carboxamide 
• 1093256-27-9 4-chloro-N-({4-chloro-3-[(3-chloro-5-ethenylphenyl)oxy]-2-fluorophenyl}methyl)-2-ethyl-1H-imidazole-5-carboxamide 
• 1093256-26-8 4-chloro-N-[(4-chloro-3-{[3-chloro-5-(cyclopropylethynyl)phenyl]oxy}-2-fluorophenyl)methyl]-2-ethyl-1H-imidazole-5-carboxamide trifluoroacetate 
• 1093256-24-6 N-({3-[(3-bromo-5-chlorophenyl)oxy]-4-chloro-2-fluorophenyl}methyl)-4-chloro-2-ethyl-1H-imidazole-5-carboxamide 

Relevant articles and documents

Design, synthesis, and calcium channel antagonist activity of new 1,4-dihydropyridines containing 4-(5)-chloro-2-ethyl-5-(4)-imidazolyl substituent

A series of dialkyl, dicycloalkyl, and diaryl ester analogues of nifedipine, in which the ortho-nitro phenyl group at position 4 is replaced by the 4-(5)-chloro-2-ethyl-5-(4)-imidazolyl substituent, were synthesized and evaluated as calcium channel antago

Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase

A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-amide biarylether scaffold has been identified and shown to possess potent antiviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus. X-ray crystallography of inhibitors bound to reverse transcriptase, including a structure of the Y188L RT protein, was used extensively to help identify and optimize the key hydrogen-bonding motif. This led directly to the design of compound 43 that exhibits remarkable antiviral activity (EC50 1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic profile across multiple species.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

Process for synthesizing 4-halo-5-(hydroxymethyl) imidazole compounds

A process for preparing, on an industrial scale, 4-halo-5-(hydroxymethyl) imidazole compounds that are useful as intermediates for medicines. A 4-chloro-5-(hydroxymethyl) imidazole compound, a 4-bromo-5-(hydroxymethyl) imidazole compound or a like compound is synthesized by reacting a 4,5-bis(hydroxymethyl) imidazole compound with a halogenating agent such as an N-chlorosuccinimide, an N-bromosuccinimide, a chlorinated isocyanuric acid compound or the like compound.

Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability

We have identified GR138950, a potent antagonist of the angiotensin II receptor with high oral bioavailability, as our second drug candidate to GR117289. Using GR117289, a compound with moderate bioavailability (20%) in man as a lead, we pursued a strategy aimed at enhancing bioavailability. The strategy was based on SAR established around the diacid GR117289, and from this, it was proposed that a monoacid, in particular a trifluoromethanesulfonamide, should be better absorbed after oral administration and have enhanced oral bioavailability. This led to the identification of GR138950, a potent antihypertensive agent in the renal hypertensive rat, causing sustained falls in blood pressure after oral administration. Oral bioavailability of GR138950 in rats and dogs is high, confirming that GR138950 is well absorbed after oral administration. Moreover, the low plasma clearance and long plasma half-life suggest that this compound will be suitable for once a day administration. Furthermore, the preliminary data indicate that the high bioavailability of GR138950 seen in rats and dogs translates to man. These results demonstrate clearly that GR138950 has the potential to be a clinically effective antihypertensive agent. Further studies are in progress to evaluate GR138950 in the treatment of hypertension.